UNIVERSITY OF SOUTHERN CALIFORNIA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
Completed
- Conditions
- Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
- Interventions
- Drug: combined oral contraceptives
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 64
- Registration Number
- NCT01953211
- Locations
- 🇺🇸
LAC and USC Medical Center, Los Angeles, California, United States
Harnessing mHealth and Social Support to Improve Diabetes Related Health Behavior for Inner-city Patients
Not Applicable
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Behavioral: TExT MEDBehavioral: FANS
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 44
- Registration Number
- NCT01945996
- Locations
- 🇺🇸
LAC+USC, Los Angeles, California, United States
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
Phase 2
Withdrawn
- Conditions
- Endometrial AdenocarcinomaStage IA Endometrial CarcinomaRecurrent Endometrial CarcinomaStage IIIA Endometrial CarcinomaStage IIIC Endometrial CarcinomaStage IVA Endometrial CarcinomaStage IVB Endometrial CarcinomaAtypical Endometrial HyperplasiaStage IB Endometrial CarcinomaStage II Endometrial Carcinoma
- Interventions
- Device: levonorgestrel-releasing intrauterine systemDrug: megestrol acetateOther: laboratory biomarker analysisOther: questionnaire administration
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT01943058
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT01915069
- Locations
- 🇺🇸
University of Southern California Fertility Clinic, Los Angeles, California, United States
Resistance Training and Protein Supplementation for Prostate Cancer Survivors
Not Applicable
Completed
- Conditions
- Prostate Cancer
- Interventions
- Behavioral: exercise interventionDietary Supplement: nutritional supplementationProcedure: quality-of-life assessmentOther: questionnaire administrationOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 43
- Registration Number
- NCT01909440
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Guided Imagery Intervention for Obese Latino Adolescents
Not Applicable
Completed
- Conditions
- ObesityMetabolic SyndromeInsulin Resistance
- Interventions
- Behavioral: Digital StorytellingBehavioral: Guided Imagery
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 51
- Registration Number
- NCT01895595
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- HER2-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
- Interventions
- Drug: capecitabineDrug: cyclophosphamideDrug: lapatinib ditosylateBiological: trastuzumabOther: laboratory biomarker analysis
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT01873833
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Phase 2
- Conditions
- Stage IIA Rectal CancerSignet Ring Adenocarcinoma of the RectumStage IIC Rectal CancerStage IIIA Rectal CancerStage IIIB Rectal CancerMucinous Adenocarcinoma of the RectumStage IIB Rectal CancerStage IIIC Rectal Cancer
- Interventions
- Biological: bevacizumabDrug: oxaliplatinDrug: leucovorin calciumDrug: fluorouracilOther: laboratory biomarker analysis
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 17
- Registration Number
- NCT01871571
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Terminated
- Conditions
- Stage IV Prostate CancerAdenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer
- Interventions
- Drug: orteronelOther: laboratory biomarker analysis
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT01866423
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Behavioral Economics Incentives for Health Management
Not Applicable
Completed
- Conditions
- Type 2 DiabetesObesity
- Interventions
- Behavioral: Lottery InsuranceBehavioral: Standard Lottery
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 152
- Registration Number
- NCT01823458
- Locations
- 🇺🇸
QueensCare Family Clinics, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath